Soligenix, Inc. (NASDAQ: SNGX) noted its shares falling hard Tuesday. The Princeton, New Jersey-based company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor.
Dr. Philipson is considered an expert in United States (U.S.) economic policy, particularly health care policy, and frequently appears on major media outlets, including Forbes, The Economist, The Wall Street Journal, The New York Times, CNN, BBC, CBS, ABC, CNBC, Fox News, Fox Business, Newsmax, Yahoo Finance, American Voice, Bloomberg, and CSPAN. He currently serves as Managing Partner of the venture capital firm MEDA Ventures; serves on several corporate boards; and has co-founded several companies, including Precision Health Economics LLC, with an exit in 2015 (currently owned by Blackstone).
His government service includes a full-time position as vice chairman and acting chairman of President Trump's White House Council of Economic Advisers from 2017 to 2020. He previously served as a senior economic adviser to the head of the U.S. Food and Drug Administration (FDA) and a senior economic advisor to the head of the Centers for Medicare and Medicaid Services.
SLGX shares ditched 44 cents, or 18.9%, to $1.89.
Related Stories
